KCM
ANAB icon

Kornitzer Capital Management’s AnaptysBio ANAB Stock Holding History

Kornitzer Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-126,756
Closed -$12.8M – 469
2017
Q4 		$12.8M Buy
+126,756
New +$9.33M 0.22% 140

Other funds holding ANAB

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Kornitzer Capital Management's ANAB Position: Q1 2018 in Review

Kornitzer Capital Management sold out of AnaptysBio (ANAB) in Q1 2018, closing a stake of 126,756 shares — an estimated $12.8M sold.

Kornitzer Capital Management first reported a position in ANAB in Q4 2017 and held it in 1 quarter. The position peaked at $12.8M in Q4 2017. 134 funds tracked by Wall St. Rank hold ANAB as of Q1 2018.

  • Kornitzer Capital Management reported no remaining AnaptysBio position as of Q1 2018 after selling out during the quarter.
  • Kornitzer Capital Management sold 126,756 AnaptysBio shares in Q1 2018, an estimated $12.8M.
  • Kornitzer Capital Management first reported a position in AnaptysBio in Q4 2017 and held it in 1 quarter.
  • Kornitzer Capital Management's AnaptysBio position peaked at $12.8M in Q4 2017.
  • 134 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2018.

Based on Kornitzer Capital Management's 13F filing for Q1 2018, filed 30 Apr 2018.